Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
Pirazzoli V, Ayeni D, Meador CB, Sanganahalli BG, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K. Pirazzoli V, et al. Among authors: pao w. Clin Cancer Res. 2016 Jan 15;22(2):426-35. doi: 10.1158/1078-0432.CCR-15-0620. Epub 2015 Sep 4. Clin Cancer Res. 2016. PMID: 26341921 Free PMC article.
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W. Takezawa K, et al. Among authors: pao w. Cancer Discov. 2012 Oct;2(10):922-33. doi: 10.1158/2159-8290.CD-12-0108. Epub 2012 Sep 5. Cancer Discov. 2012. PMID: 22956644 Free PMC article.
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.
Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Jia P, et al. Among authors: pao w. Genome Res. 2013 Sep;23(9):1434-45. doi: 10.1101/gr.152322.112. Epub 2013 Jun 3. Genome Res. 2013. PMID: 23733853 Free PMC article.
Beyond histology: translating tumor genotypes into clinically effective targeted therapies.
Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Meador CB, et al. Among authors: pao w. Clin Cancer Res. 2014 May 1;20(9):2264-75. doi: 10.1158/1078-0432.CCR-13-1591. Epub 2014 Mar 5. Clin Cancer Res. 2014. PMID: 24599935 Free PMC article. Review.
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.
Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K. Pirazzoli V, et al. Among authors: pao w. Cell Rep. 2014 May 22;7(4):999-1008. doi: 10.1016/j.celrep.2014.04.014. Epub 2014 May 9. Cell Rep. 2014. PMID: 24813888 Free PMC article.
Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.
Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W. Meador CB, et al. Among authors: pao w. Mol Cancer Ther. 2015 Feb;14(2):542-52. doi: 10.1158/1535-7163.MCT-14-0723. Epub 2014 Dec 4. Mol Cancer Ther. 2015. PMID: 25477325 Free PMC article.
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J. Amato KR, et al. Among authors: pao w. Cancer Res. 2016 Jan 15;76(2):305-18. doi: 10.1158/0008-5472.CAN-15-0717. Epub 2016 Jan 7. Cancer Res. 2016. PMID: 26744526 Free PMC article.
243 results